Wharton's jelly-derived mesenchymal stem cells therapy (Mahidol University)

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameWharton's jelly-derived mesenchymal stem cells therapy (Mahidol University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsBrain Injuries
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryThailand
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMahidol University
China Registration ClassN/A

Develop Information

Active CompaniesSiriraj HospitalMahidol University
Inactive CompaniesN/A
Active IndicationsBrain Injuries
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A